Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Lyka Labs
Small Cap•499 Employees•IPO 1995
Current Price
₹60.77
0.08 (0.13%)Updated
Today's Range
₹59.20
₹61.80
₹60.77
52 Week Range
52W Low₹60.04
52W High₹128.78
₹60.77
Downside1.22%
Upside111.91%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹240.19 Cr
Market Cap
Total market value of companyP/E Ratio
116.88
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
3.39
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹0.57
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
-1.55%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
9.91%
ROCE
Return on Capital Employed. >15% is goodNet Margin
1.50%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
17.63%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
9.70%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-35.40%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.38
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹29.01
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
58.20%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Promoter holding has significantly increased from 47.80% in June 2022 to 58.16% by September 2025, indicating strong confidence from the management in the company's future prospects and stability.
- •The company maintains a healthy financial structure with a low debt-to-equity ratio of 0.38, indicating prudent financial management and reduced reliance on external borrowings, which is positive for long-term stability.
Weaknesses
5 points- •Lyka Labs trades at a relatively high Price-to-Earnings (P/E) ratio of 45.00, which is higher than several industry peers, suggesting that the stock might be overvalued compared to its current earnings.
- •The company experienced a substantial decline in quarterly profit, with a -35.40% variation in net profit for the latest quarter, raising concerns about recent profitability and operational efficiency.
Opportunities
3 points- •Operating within the robust Pharmaceuticals industry, Lyka Labs can capitalize on increasing global healthcare demand, expanding markets, and advancements in medical research to drive future growth.
- •Potential for Lyka Labs to explore new product lines or therapeutic areas, along with expanding into untapped international markets, could significantly boost revenue and market share in the long term.
Threats
4 points- •Lyka Labs faces intense competition from larger, more established players in the pharmaceutical sector, which possess greater resources for R&D, marketing, and market penetration, potentially limiting growth.
- •Strict and evolving regulatory landscape in the pharmaceutical industry poses a continuous threat, as compliance costs and potential delays in product approvals could impact Lyka Labs' operations and profitability.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹67.18 | +₹6.41 | +10.55% |
| R3 | ₹64.58 | +₹3.81 | +6.27% |
| R2 | ₹63.19 | +₹2.42 | +3.98% |
| R1 | ₹61.98 | +₹1.21 | +1.99% |
| PIVOT | ₹60.59 | -0.18 | -0.30% |
| CURRENT | ₹60.77 | - | - |
| S1 | ₹54.18 | -₹6.59 | -10.84% |
| S2 | ₹56.78 | -₹3.99 | -6.57% |
| S3 | ₹57.99 | -₹2.78 | -4.57% |
| S4 | ₹59.38 | -₹1.39 | -2.29% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-7.0% vs avg
0.32L
(02 Mar 2026)Delivery %-0.0% vs avg
67.3%
(02 Mar 2026)Avg Volume (20D)20-day average
0.34L
(03 Feb - 02 Mar)Avg Delivery %Trend ↓
67.4%
(03 Feb - 02 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Valiant Laboratories Ltd
457.00 %
Highest Dividend Yield
Sun Pharmaceutical Industries Ltd
0.91 %
Peer Comparison
| Company Name |
|---|
 Aarey Drugs & Pharmaceuticals Ltd |
 Bafna Pharmaceuticals Ltd |
 Nectar Lifescience Ltd |
 SMS Lifesciences India Ltd |
 Sun Pharmaceutical Industries Ltd |
 Valiant Laboratories Ltd |
 Zim Laboratories Ltd |
About
Lyka Labs Ltd
Lyka Labs Limited is an Indian pharmaceutical company with a comprehensive business model encompassing the development, manufacturing, and marketing of a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Their product portfolio spans numerous therapeutic areas, demonstrating a significant presence in the Indian pharmaceutical market and beyond.
The company's manufacturing capabilities are extensive, producing a diverse array of formulations including topical treatments (emollients, steroids, antifungals, antibacterials, acne medications), pain relievers, anti-aging products, hair care solutions, and sunscreens. Beyond dermatological products, Lyka Labs manufactures products for various other therapeutic segments, such as gastroenterology, anti-infectives, and even intensive care medications, showcasing their versatility in manufacturing different dosage forms.
Lyka Labs' product offerings extend to a broad spectrum of dosage forms, including injections, creams, ointments, foams, gels, and lotions, catering to a wide range of patient needs and administration preferences. This diverse portfolio also includes nutraceuticals, indicating a focus on both pharmaceutical and health supplement markets.
A significant aspect of Lyka Labs' business is its provision of contract manufacturing services to other large pharmaceutical companies. This service extends beyond simply manufacturing; it also includes offering crucial technical assistance, encompassing manufacturing know-how, facility support, and the provision of vital technical data such as stability testing data, impurity profiles, and bioequivalence (BA/BE) clinical study data. This demonstrates a commitment to providing comprehensive support to its clients.
Finally, Lyka Labs' operations extend beyond the domestic market, as the company actively exports its products internationally, indicating a successful penetration of international markets and a growing global presence. In summary, Lyka Labs is a well-established player in the pharmaceutical industry, combining internal product development and manufacturing with a significant contract manufacturing and technical services division, all while engaging in both domestic and international markets.
COMPANY FACTS - LYKALABS
Registered Address
Ground floor, Spencer Building,, 30, Forjett Street, Grant Road (West)
Mumbai
MAHARASHTRA
IN
Tel: 912266112200
Website:https://www.lykalabs.com/
Investor Relations:http://www.lykalabs.com/annual_reports.html
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 499
IPO Date: 09/02/1995
MANAGEMENT - LYKALABS
Mr. Kunal Gandhi
Chief Executive Officer, Managing Director
Mr. Yogesh Shah
Chief Financial Officer, Additional Executive Director
Mr. Shekhar Singh
Company Secretary and Compliance Officer
Mr. Prashant Godha
Additional Director
Mr. Shashil Mendonsa
Additional Director
Shri. Vinod Shanbhag
Additional Independent Director
Mr. Neeraj Golas
Additional Non-Executive Independent Director
Ms. Dhara Shah
Additional Non-Executive Independent Director
Investor Questions Answered
Lyka Labs Ltd (LYKALABS) Stock FAQs
Get answers to the most common questions about Lyka Labs Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Lyka Labs Ltd (LYKALABS) is ₹60.77. Today, the stock has gained by ₹0.08 (0.13%), trading in a range of ₹59.2 to ₹61.8. The stock opened at ₹61.8 with a trading volume of 27,173 shares.
Lyka Labs Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹240.19 crores, P/E ratio of 116.88, ROE of -1.55%, and ROCE of 9.91%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Lyka Labs Ltd (LYKALABS) is ₹128.78, while the 52-week low is ₹60.04. Currently trading at ₹60.77, the stock is 1.1% away from its 52-week low and 52.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Lyka Labs Ltd stock at ₹60.77 depends on multiple factors. The stock is currently trading with a P/E ratio of 116.88 and P/B ratio of N/A. Today's performance shows a gain of 0.13%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Lyka Labs Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹60.77, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Lyka Labs Ltd's key financial metrics include: P/E Ratio: 116.88, P/B Ratio: N/A, ROE: -1.55%, ROCE: 9.91%, Dividend Yield: 0.00%, EPS: ₹0.57, Book Value: ₹29.01, Debt-to-Equity: 0.38, and Current Ratio: N/A. The company's market cap stands at ₹240.19 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Lyka Labs Ltd stock opened at ₹61.8 and is currently trading at ₹60.77, showing a gain of ₹0.08 (0.13%). The intraday high is ₹61.8 and low is ₹59.2. The trading volume stands at 27,173 shares, indicating moderate market participation today.
Lyka Labs Ltd has a Price-to-Earnings (P/E) ratio of 116.88, which means investors are willing to pay ₹116.88 for every ₹1 of earnings. With an EPS of ₹0.57, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Lyka Labs Ltd has a market capitalization of ₹240.19 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹60.77) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Lyka Labs Ltd has a book value of ₹29.01 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹60.77, which is 109.5% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Lyka Labs Ltd has a Return on Equity (ROE) of -1.55% and Return on Capital Employed (ROCE) of 9.91%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Lyka Labs Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Lyka Labs Ltd has a debt-to-equity ratio of 0.38, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Lyka Labs Ltd has an Earnings Per Share (EPS) of ₹0.57, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹60.77 and P/E ratio of 116.88, investors are paying 116.88 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Lyka Labs Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Lyka Labs Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Lyka Labs Ltd stock, consider: 1) Fundamental Analysis - Review P/E (116.88), ROE (-1.55%), debt-to-equity (0.38), and growth rates. 2) Technical Analysis - Check 52-week range (₹60.04 - ₹128.78), moving averages, and chart patterns. 3) Valuation - Compare current price (₹60.77) with book value (₹29.01) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Lyka Labs Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹60.77 is 508x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Lyka Labs Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹60.04 - ₹128.78). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.38 indicates leverage. 4) Liquidity Risk - Based on trading volume of 27,173 shares. 5) Valuation Risk - P/E of 116.88 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Lyka Labs Ltd operates in the industry with key metrics: P/E ratio of 116.88, ROE of -1.55%, market cap of ₹240.19 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.38), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Lyka Labs Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹60.77, with a 52-week range of ₹60.04 to ₹128.78. Based on fundamentals like P/E (116.88), ROE (-1.55%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Lyka Labs Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹60.77. 2) Fundamental Deterioration - Declining ROE (currently -1.55%), increasing debt (D/E: 0.38), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Lyka Labs Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu